Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s successBy Mario Cazombo / November 4, 2025 Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.
Book Review: The Financial Restructuring Tool Set August 6, 2025 / Book Reviews, Corporate Finance, Drivers of Value, Economics, Financial Statement Analysis, General
